DETERMARX Trademark

Trademark Overview

On Wednesday, November 6, 2019, a trademark application was filed for DETERMARX with the United States Patent and Trademark Office. The USPTO has given the DETERMARX trademark a serial number of 88980839. The federal status of this trademark filing is REGISTERED as of Tuesday, May 11, 2021. This trademark is owned by OncoCyte Corporation. The DETERMARX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing reagent sample testing and diagnostic services for others in the field of cancer testing, tumor testing, and screening for the purpose of evaluating risk factors, the probability of cancer reoccurrence, and need for subsequent therapeutic treatment
determarx

General Information

Serial Number88980839
Word MarkDETERMARX
Filing DateWednesday, November 6, 2019
Status700 - REGISTERED
Status DateTuesday, May 11, 2021
Registration Number6350018
Registration DateTuesday, May 11, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 2, 2020

Trademark Statements

Goods and ServicesProviding reagent sample testing and diagnostic services for others in the field of cancer testing, tumor testing, and screening for the purpose of evaluating risk factors, the probability of cancer reoccurrence, and need for subsequent therapeutic treatment

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, November 14, 2019
Primary Code042
First Use Anywhere DateFriday, January 31, 2020
First Use In Commerce DateFriday, January 31, 2020

Trademark Owner History

Party NameOncoCyte Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92618
US
Party NameOncoCyte Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIrvine, CA 92618
US
Party NameOncoCyte Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAlameda, CA 94501
US

Trademark Events

Event DateEvent Description
Saturday, November 9, 2019NEW APPLICATION ENTERED
Thursday, November 14, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 29, 2020ASSIGNED TO EXAMINER
Monday, February 3, 2020NON-FINAL ACTION WRITTEN
Monday, February 3, 2020NON-FINAL ACTION E-MAILED
Monday, February 3, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 20, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 20, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 20, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 21, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 28, 2020ASSIGNED TO LIE
Wednesday, May 13, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 2, 2020PUBLISHED FOR OPPOSITION
Tuesday, June 2, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, June 17, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, June 17, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, June 17, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, July 28, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 28, 2021TEAS STATEMENT OF USE RECEIVED
Thursday, January 28, 2021TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, February 16, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, December 7, 2020DIVISIONAL REQUEST RECEIVED
Tuesday, March 9, 2021DIVISIONAL PROCESSING COMPLETE
Thursday, January 28, 2021USE AMENDMENT FILED
Tuesday, March 9, 2021STATEMENT OF USE PROCESSING COMPLETE
Thursday, April 8, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, April 9, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, May 11, 2021REGISTERED-PRINCIPAL REGISTER
Monday, May 11, 2026COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

determarx testing cancer probability factors risk reoccurrence need treatment therapeutic subsequent